JPWO2020009248A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020009248A5 JPWO2020009248A5 JP2020529077A JP2020529077A JPWO2020009248A5 JP WO2020009248 A5 JPWO2020009248 A5 JP WO2020009248A5 JP 2020529077 A JP2020529077 A JP 2020529077A JP 2020529077 A JP2020529077 A JP 2020529077A JP WO2020009248 A5 JPWO2020009248 A5 JP WO2020009248A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- tissue
- fibrosis
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001519 tissue Anatomy 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 206010016654 Fibrosis Diseases 0.000 claims 11
- 230000004761 fibrosis Effects 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 230000001629 suppression Effects 0.000 claims 4
- 102000008186 Collagen Human genes 0.000 claims 3
- 108010035532 Collagen Proteins 0.000 claims 3
- 208000010412 Glaucoma Diseases 0.000 claims 3
- 229920001436 collagen Polymers 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 230000014509 gene expression Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 102000003964 Histone deacetylase Human genes 0.000 claims 2
- 108090000353 Histone deacetylase Proteins 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 208000002352 blister Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000000795 conjunctiva Anatomy 0.000 claims 2
- 210000004748 cultured cell Anatomy 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 210000001525 retina Anatomy 0.000 claims 2
- 230000036573 scar formation Effects 0.000 claims 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 claims 1
- 102100031168 CCN family member 2 Human genes 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 108010002156 Depsipeptides Proteins 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims 1
- 101710159002 L-lactate oxidase Proteins 0.000 claims 1
- 101150043981 LOXL2 gene Proteins 0.000 claims 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims 1
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 claims 1
- 108050000761 Serpin Proteins 0.000 claims 1
- 102000008847 Serpin Human genes 0.000 claims 1
- 108010046722 Thrombospondin 1 Proteins 0.000 claims 1
- 102100036034 Thrombospondin-1 Human genes 0.000 claims 1
- 102100029529 Thrombospondin-2 Human genes 0.000 claims 1
- 102000005354 Tissue Inhibitor of Metalloproteinase-2 Human genes 0.000 claims 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 claims 1
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 claims 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- -1 depsipeptide compound Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003090 exacerbative effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000003001 serine protease inhibitor Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 108010060887 thrombospondin 2 Proteins 0.000 claims 1
- 210000001585 trabecular meshwork Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024131200A JP7763438B2 (ja) | 2018-07-04 | 2024-08-07 | 眼組織の線維化抑制用組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018127738 | 2018-07-04 | ||
| JP2018127738 | 2018-07-04 | ||
| PCT/JP2019/027233 WO2020009248A1 (ja) | 2018-07-04 | 2019-07-03 | 眼組織の線維化抑制用組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131200A Division JP7763438B2 (ja) | 2018-07-04 | 2024-08-07 | 眼組織の線維化抑制用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020009248A1 JPWO2020009248A1 (ja) | 2021-08-12 |
| JPWO2020009248A5 true JPWO2020009248A5 (enExample) | 2022-08-09 |
| JP7542799B2 JP7542799B2 (ja) | 2024-09-02 |
Family
ID=69059196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529077A Active JP7542799B2 (ja) | 2018-07-04 | 2019-07-03 | 眼組織の線維化抑制用組成物 |
| JP2024131200A Active JP7763438B2 (ja) | 2018-07-04 | 2024-08-07 | 眼組織の線維化抑制用組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131200A Active JP7763438B2 (ja) | 2018-07-04 | 2024-08-07 | 眼組織の線維化抑制用組成物 |
Country Status (2)
| Country | Link |
|---|---|
| JP (2) | JP7542799B2 (enExample) |
| WO (1) | WO2020009248A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020009248A1 (ja) * | 2018-07-04 | 2020-01-09 | 京都府公立大学法人 | 眼組織の線維化抑制用組成物 |
| CN113057142B (zh) * | 2021-03-30 | 2022-12-09 | 四川大学华西医院 | 一种视网膜内和/或视网膜下纤维化动物模型的构建方法 |
| WO2023196555A1 (en) * | 2022-04-08 | 2023-10-12 | University Of North Texas Health Science Center At Fort Worth | Treatment for ocular fibrosis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405274B2 (en) * | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| MX2013007936A (es) * | 2011-01-06 | 2013-08-09 | Glaxo Group Ltd | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta. |
| WO2013100208A1 (ja) * | 2011-12-28 | 2013-07-04 | 京都府公立大学法人 | 角膜内皮細胞の培養正常化 |
| WO2015015654A1 (ja) * | 2013-07-30 | 2015-02-05 | 京都府公立大学法人 | 角膜内皮ｅｃｍ治療薬 |
| JP2016113379A (ja) * | 2014-12-11 | 2016-06-23 | 京都府公立大学法人 | 分子標的薬を用いる腫瘍治療及び予防用併用薬 |
| WO2020009248A1 (ja) * | 2018-07-04 | 2020-01-09 | 京都府公立大学法人 | 眼組織の線維化抑制用組成物 |
-
2019
- 2019-07-03 WO PCT/JP2019/027233 patent/WO2020009248A1/ja not_active Ceased
- 2019-07-03 JP JP2020529077A patent/JP7542799B2/ja active Active
-
2024
- 2024-08-07 JP JP2024131200A patent/JP7763438B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020009248A5 (enExample) | ||
| CA3045733C (en) | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases | |
| RU2012107109A (ru) | Бициклическое соединение и его применение для медицинских целей | |
| EA019867B1 (ru) | Водные офтальмологические препараты | |
| RU2632107C2 (ru) | Пероральная фармацевтическая композиция для профилактики или лечения синдрома "сухого глаза", содержащая ребамипид или его предшественник | |
| EP3733177B1 (en) | Composition for protecting cornea | |
| JP2017531022A (ja) | シクロスポリン及びトレハロースを含む眼科用組成物 | |
| CN107708738A (zh) | 含有柠檬酸酯的贮库制剂 | |
| KR101404151B1 (ko) | 안과 질환의 예방 및 치료용 약학 조성물 | |
| JP2013510852A5 (enExample) | ||
| JP2010514733A5 (enExample) | ||
| JP2024041947A (ja) | 眼圧下降増強剤 | |
| CN107735091B (zh) | 包含伊马替尼作为活性成分的用于预防和治疗干眼病的药物组合物 | |
| JP2019534296A5 (enExample) | ||
| JPWO2020009248A1 (ja) | 眼組織の線維化抑制用組成物 | |
| JP6928479B2 (ja) | 拒絶反応抑制剤 | |
| JP2016056207A (ja) | プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法 | |
| Deng et al. | The use of voriconazole in the management of post-penetrating keratoplasty Paecilomyces keratitis | |
| KR20120081585A (ko) | 안질환을 치료하기 위한 이소티오졸 | |
| Huynh et al. | Delayed posttraumatic Propionibacterium acnes endophthalmitis in a child | |
| WO2001013911A1 (fr) | Agents inhibiteurs des troubles d'hypertension arterielle | |
| JP7429500B2 (ja) | 角膜上皮障害治療剤 | |
| Kozomara et al. | Simultaneous bilateral implantation of ex-press glaucoma shunt for secondary glaucoma treatment due to axenfeld-rieger syndrome: a case report | |
| JPWO2021125800A5 (enExample) | ||
| Mohamadi et al. | The effect of phacoemulsification with posterior chamber intraocular lens implantation on intraocular pressure and anterior chamber depth |